Chemotherapy | Surviving Mesothelioma

Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival

German surgeons are reporting on a potential new way to improve outcomes for people with malignant pleural mesothelioma by infusing chemotherapy drugs in an isolated area and then removing them. In an article in OncoTargets and Therapy, surgical oncologists from Burghausen, Germany say they were prompted to test the new technique after radical mesothelioma surgery “failed to translate into a definite survival advantage.” Mesothelioma Treatment Risks Although … Continue reading Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival »

Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma

A new drug designed to treat recurrent malignant mesothelioma while minimizing side effects has failed to meet expectations. Anetumab ravtansine, is an antibody-drug conjugate (ADC) developed with biotechnology firms ImmunoGen and MorphoSys and owned by Bayer.  It had been the focus of a Phase II clinical trial for pleural mesothelioma. The trial has now been stopped. Understanding ADCs Many of the most dangerous side effects of … Continue reading Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma »

Study to Test New Three-Drug Treatment for Pleural Mesothelioma

The makers of a VEGF-inhibitor called nintedanib are recruiting patients with unresectable pleural mesothelioma for a Phase III clinical trial of the drug in combination with standard chemotherapy. The multicenter trial sponsored by drug maker Boehringer Ingelheim will eventually include a total of 450 mesothelioma patients, but preliminary results from the first 87 patients look promising.  According to data presented at the 2017 American Society of Clinical Oncology … Continue reading Study to Test New Three-Drug Treatment for Pleural Mesothelioma »

Compound in Broccoli May Enhance Mesothelioma Treatment with Cisplatin

There is new evidence that a compound found in cruciferous vegetables like broccoli and cabbage may enhance the anticancer benefits of the platinum-based drug cisplatin in the treatment of pleural mesothelioma. Although malignant mesothelioma is highly resistant to conventional cancer treatments, most mesothelioma patients will receive chemotherapy with cisplatin and pemetrexed (Alimta) as part of a multi-modal approach to treatment. Now, researchers Yoon-Jin and Sang-Han … Continue reading Compound in Broccoli May Enhance Mesothelioma Treatment with Cisplatin »

Boosting Mesothelioma Survival with VEGF-Inhibitor

The VEGF inhibitor cediranib may not yet be out of the running as a mesothelioma treatment. Although previous studies have found it to have dose-limiting side effects, a new study in the Journal of Thoracic Oncology finds that, at the right dose, it could boost the effectiveness of standard mesothelioma chemotherapy. What is Cediranib? Cediranib, an oral drug made by Astra Zeneca, is a powerful … Continue reading Boosting Mesothelioma Survival with VEGF-Inhibitor »

Standardization Needed for Peritoneal Mesothelioma Treatment

Mesothelioma researchers in Belgium and the US have some good news and some bad news about peritoneal mesothelioma treatment. The good news is that the combination of cytoreductive surgery to remove the mesothelioma tumor and intraperitoneal chemotherapy (HIPEC) to kill residual cancer cells improves mesothelioma survival. Overall, the method is so effective that the authors say the combination should now be considered standard of care … Continue reading Standardization Needed for Peritoneal Mesothelioma Treatment »

VEGF-Inhibitor Looks Promising for Malignant Mesothelioma

There is more encouraging news about the monoclonal antibody bevacizumab (Avastin) and its potential to boost the effectiveness of chemotherapy for people with malignant pleural mesothelioma. A pair of oncology researchers from Texas have just released their summary of the the most recent published studies on bevacizumab. They conclude that, for the right patients, bevacizumab may improve mesothelioma outcomes and extend survival by blocking tumor blood … Continue reading VEGF-Inhibitor Looks Promising for Malignant Mesothelioma »

Additional Chemotherapy Extends Survival in Relapsed Mesothelioma Patients

Black American Patient

Mesothelioma patients who experience a recurrence of their asbestos cancer after radical surgery may live longer if they undergo additional rounds of chemotherapy. That conclusion comes from a group of Japanese researchers who performed a retrospective review of 59 consecutive pleural mesothelioma patients who had multimodal mesothelioma treatment that included extrapleural pneumonectomy (EPP) surgery. Study subjects had been treated for malignant mesothelioma at Hyogo College … Continue reading Additional Chemotherapy Extends Survival in Relapsed Mesothelioma Patients »

New Combination Treatment for Rare Mesothelioma Subtypes

woman mesothelioma doctor holds syringe

An enzyme shown to help fight melanoma and liver cancer may offer new hope to patients with some of the most treatment-resistant mesothelioma tumors. Malignant mesothelioma is a rare, asbestos-linked cancer of internal membranes. Although all forms are highly resistant to standard cancer therapies, the sarcomatoid and biphasic subtypes – which are the rarest forms of mesothelioma – typically carry the worst prognosis. But a … Continue reading New Combination Treatment for Rare Mesothelioma Subtypes »

New Drug Delivery System Doubles Mesothelioma Survival

A new method for delivering cancer-fighting drugs directly into mesothelioma tumors has been shown to more that double mesothelioma survival in a new animal study. Surgeons, pathologists, biomedical engineers and chemists from Boston University and Harvard Medical School used specially-formulated expanding nanoparticles to deliver high doses of the drug paclitaxel into mice with malignant mesothelioma. By loading the drug into nanoparticles that expand in the … Continue reading New Drug Delivery System Doubles Mesothelioma Survival »

Get your free copy of
“Surviving Mesothelioma” Today!